SCHEMBL8080299

SCHEMBL8080299

NCC(NS(=O)(=O)c1ccccc1Cl)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGAV P06756 7/20 0.66
SLC1A3 P43003 1/20 0.62
SLC1A2 P43004 1/20 0.62
SLC1A1 P43005 1/20 0.62
HTT P42858 1/20 0.53
CTSL P07711 2/20 0.49
CTSS P25774 2/20 0.49
CTSK P43235 2/20 0.49
CTSB P07858 1/20 0.49
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.47
PKM P14618 1/20 0.47
ALDH1A1 P00352 1/20 0.47
BMP1 P13497 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734803 0.87 ITGAV (0.67) ITGAVSLC1A3SLC1A2SLC1A1HTT
SCHEMBL1734801 0.87 ITGAV (0.67) ITGAVSLC1A3SLC1A2SLC1A1HTT
SCHEMBL8093821 0.82 GBA1 (0.56) ITGAVALDH1A1MMP2MMP9
SCHEMBL27575200 0.80 SLC1A3 (0.64) ITGAVSLC1A3SLC1A2SLC1A1KDM4E
SCHEMBL5840519 0.80 SLC1A3 (0.64) ITGAVSLC1A3SLC1A2SLC1A1KDM4E
SCHEMBL383079 0.80 MMP2 (0.61) SLC1A3SLC1A2SLC1A1ALDH1A1MMP2
SCHEMBL6500230 0.80 MMP2 (0.61) SLC1A3SLC1A2SLC1A1ALDH1A1MMP2
Hydrochloric Acid SCHEMBL6499290 0.79 SLC1A3 (0.62) ITGAVSLC1A3SLC1A2SLC1A1KDM4E
Hydrochloric Acid SCHEMBL382133 0.78 MMP2 (0.59) SLC1A3SLC1A2SLC1A1ALDH1A1MMP2
Hydrochloric Acid SCHEMBL7336920 0.78 MMP2 (0.59) SLC1A3SLC1A2SLC1A1ALDH1A1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1051625-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES Du Pont Pharmaceuticals Company (US) 2000-11-15 EP disclosed
WO-1999038014-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-29 WO disclosed